Temozolomide and Radiotherapy vs Radiotherapy Alone in Patients With IDH Wild-Type Glioblastoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial
Clin. Cancer Res 2022 Jun 13;28(12)2527-2535, CMS Tesileanu, M Sanson, W Wick, AA Brandes, PM Clement, SC Erridge, MA Vogelbaum, AK Nowak, JF Baurain, WP Mason, H Wheeler, OL Chinot, S Gill, M Griffin, L Rogers, W Taal, R Rudà, M Weller, C McBain, ME van Linde, K Aldape, RB Jenkins, JM Kros, P Wesseling, A von Deimling, Y Hoogstrate, I de Heer, PN Atmodimedjo, HJ Dubbink, RWW Brouwer, WFJ van IJcken, KJ Cheung, V Golfinopoulos, BG Baumert, T Gorlia, PJ French, MJ van den BentFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.